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The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused
by a bat-derived beta-coronavirus, named SARS-CoV2. It shares homology with SARS and MERS-CoV, re-
sponsible for past outbreaks in China and in Middle East. SARS-CoV2 spread from China where the first infec-
tions were described in December 2019 and is responsible for the respiratory symptoms that can lead to acute
respiratory distress syndrome. A cytokine storm has been shown in patients who develop fatal complications, as
observed in past coronavirus infections. The management includes ventilatory support and broad-spectrum
antiviral drugs, empirically utilized, as a targeted therapy and vaccines have not been developed. Based upon our
limited knowledge on the pathogenesis of CoViD-19, a potential role of some anti-rheumatic drugs may be
hypothesized, acting as direct antivirals or targeting host immune response. Antimalarial drugs, commonly used
in rheumatology, may alter the lysosomal proteases that mediates the viral entry into the cell and have de-
monstrated efficacy in improving the infection. Anti-IL-1 and anti-IL-6 may interfere with the cytokine storm in
severe cases and use of tocilizumab has shown good outcomes in a small cohort. Baricitinib has both antiviral
and anti-inflammatory properties. Checkpoints inhibitors such as anti-CD200 and anti-PD1 could have a role in
the treatment of CoViD-19. Rheumatic disease patients taking immunosuppressive drugs should be re-
commended to maintain the chronic therapy, prevent infection by avoiding social contacts and pausing im-
munosuppressants in case of infection. National and international registries are being created to collect data on
rheumatic patients with CoViD-19.
1. SARS-CoV2 and the acute respiratory distress syndrome
Coronavirus Disease-2019 (CoViD-19) has emerged over the past
months as a clinical syndrome caused by a novel beta-Coronavirus,
named Severe Acute Respiratory Syndrome (SARS)-CoV2. It was first
reported in late December 2019 in Wuhan, China and the disease was
officially named CoViD-19 by the World Health Organization (WHO) on
February 11th, 2020 following an outbreak of acute respiratory illness
in the Hubei province. Since these earliest reports, this infection has
spread in many countries worldwide with a significant rate of infection
in Italy that currently accounts for more than 110,000 infected cases
associated with 13,155 fatalities. The WHO declared CoViD-19 a
pandemic on March 11th. The CoViD-19 pandemic has important im-
plications for patients with rheumatic diseases, particularly those un-
dergoing a variety of immunosuppressive therapies. As it seems obvious
that immunosuppressive therapy increases their risk of severe disease if
infected with CoViD-19, many patients have the tendency to stop their
immunosuppressive treatments, especially in highly impacted areas
such as the Italian Lombardy region. However, it is important to note
that many commonly used immunosuppressive drugs such as JAK ki-
nase inhibitors and tocilizumab have been proposed and/or used for the
treatment of select patients who develop a frequently fatal clinical se-
qualae known as Cytokine Release Syndrome (CRS) (also referred to as
“cytokine storm”) following CoViD-19 infection. While data are
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changing rapidly and the disease trajectories can only be hypothesized,
the issue whether to continue treating rheumatic disease patients needs
to be addressed by the field of Rheumatology and other medical sub-
specialties, since some of these agents may be beneficial for specific
phases or complications of the disease. SARS-CoV2 is a positive single
strand 30,000 nucleotide RNA virus that includes 14 open reading
frames that encode 27 proteins and belongs to the Coronaviridae family.
Its phylogenetic data are consistent with the presence of a bat reservoir
and subsequent spill over into the human population. Sequencing data
shows that SARS-CoV2 shares a high degree of sequence homology with
a betacoronavirus isolated from bats termed Bat-CoV-RaTG13, sug-
gesting that the Chinese chrysanthemum bat is the likely origin of
SARS-CoV2. Nonetheless, an unknown animal sold at the seafood
market in Wuhan has been hypothesized to act as the intermediate host,
as the first cases had common contacts in a market where no bats were
present (bats hibernate in December). In addition, SARS-CoV2 shares
79% and 50% gene homologies with the SARS Coronavirus (SARS-CoV)
that was responsible for an outbreak in 2002 and with the Middle East
Respiratory Syndrome (MERS)-CoV responsible for infections in Saudi
Arabia in 2012, respectively. Both these viruses had intermediate hosts
that included the civet and camel, respectively, with humans serving as
terminal hosts [1].""
Person-to-person transmission has already been established for
SARS-CoV2 infection and reasoned to be mediated by respiratory dro-
plets. The current data also suggests that the elderly and patients with a
compromised immune system are at a significantly higher risk and
higher mortality.
The CoViD-19 infection is suspected when patients develop fever,
cough, myalgia and fatigue, with bilateral interstitial pneumonia di-
agnosed in most patients (up to 76% in the earliest series) by ground
glass opacity and patchy infiltrates in the chest as visualized by com-
puterized tomography. Around 20% of cases rapidly worsen into re-
spiratory failure or acute respiratory distress syndrome (ARDS), re-
quiring admission to the intensive care unit (ICU) with a mortality rate
of approximately 2–3%, being highest in older age patients particularly
those with chronic diseases and who are currently hospitalized in ICUs
(up to 38%) [2–4]. Currently there are no specific drugs and/or vac-
cines for SARS-CoV2 infection, prompting the use of several broad-
spectrum antiviral molecules. In addition, an animal model to study the
disease and test potential vaccines is at present missing [5].
2. Anti-rheumatic drugs as possible therapies: antimalarials, anti-
IL6, anti-IL1 and baricitinib
Some drugs usually used in rheumatologic field and targeting the
host and its immune response seem to have the potential to interfere
with CoViD-19 infection and their potential benefit is being studied in
patients (Fig. 1). The pathogenesis of CoViD-19 remains unclear, but
modelling assays revealed a high degree of homology in the receptor
binding domains between SARS-CoV2 and SARS-CoV. All coronaviruses
express a surface glycoprotein termed a “spike” which bind to the host
receptor for viral entry that has been identified as angiotensin-con-
verting enzyme 2 receptors (ACE2r) [1], expressed by mature lung
epithelial cells, enterocytes, kidney proximal tubular cells and en-
dothelial cells [6]. After receptor binding, lysosomal proteases cleave
the spike protein releasing the signal peptide that facilitates viral entry
into the cell [7]. These mechanisms may be targeted and interrupted by
therapies such as chloroquine, an antimalarial drug, and preliminary
data demonstrate that it may have clinical benefit in the management of
CoViD-19 infected patients as determined by improved imaging and
shortening of the diseases course [8]. We should note that hydroxy-
chloroquine, which shares the same mechanism of action as chlor-
oquine but has a better safety profile and is frequently used particularly
in connective tissue disease, has a more potent anti-viral effect than
chloroquine in vitro. From the results of physiologically-based phar-
macokinetic models, a loading dose of 800 mg orally followed by
400 mg daily for four days reaches three times the potency of chlor-
oquine and is therefore a promising drug for both the prevention and
the treatment of CoViD-19, with low risk of toxicity [9]. These findings
have led to several clinical trials that are ongoing to study the efficacy
of chloroquine or hydroxychloroquine in CoViD-19 patients. Hydroxy-
chloroquine is thus being used in Italy for the treatment of CoViD-19
patients despite the absence of efficacy data in the clinical setting. In
light of these data, the recommendation for rheumatic patients
chronically taking antimalarial drugs is to not discontinue them, con-
sidering the antiviral efficacy and the immunomodulatory rather than
immunosuppressive effect.
The pulmonary complications in human CoViD-19 patients are due
to an exuberant local inflammatory response with diffuse alveolar da-
mage. Patients dying because of SARS have lung consolidation, edema
and mucopurulent material in the bronchial tree. At microscopic ex-
amination, alterations such as diffuse alveolar damage, hyaline mem-
brane and fibrin formation, neutrophils and macrophages infiltrates
were detected in the interstitium and alveoli. Similar features were
noted in the only human autopsy report available of MERS infection.
Cytokines and chemokines play a key role in the immune response
against viral infections, and their altered production has been demon-
strated in both SARS and MERS coronavirus infections. Such altered
levels have been shown to be likely due to the low synthesis of antiviral
cytokines such as interferons (IFN)α or β and in concert increased levels
of other pro-inflammatory cytokines/chemokines that have pathogenic
consequences. Among them, interleukin (IL)-1, IL-6 and other pro-in-
flammatory cytokines were shown to be significantly more elevated in
patients with severe compared to uncomplicated SARS or MERS infec-
tion [10,11]. Recent preliminary data from China reported high plasma
levels of cytokines including IL-6, related to the severity and the
prognosis of the disease with a clear implication for the occurrence of
“cytokine storm” and CRS. Tocilizumab, an anti-IL-6 receptor antibody
that has been used clinically to treat rheumatoid arthritis and other
autoimmune diseases, has been used and approved for treatment of a
variety of clinical conditions that include CRS. These have included
clinical conditions such as those associated with chimeric antigen re-
ceptor T-cell (CAR-T) therapy that appears to induce severe or life-
threatening cytokine release syndrome [12]. A single dose of tocili-
zumab was used in 21 patients in China suffering from severe
Fig. 1. Representation of possible mechanisms of action of anti-rheumatic
drugs in coronavirus infection. AAK1 = AP2-associated protein kinase 1;
SARS = severe acute respiratory syndrome.
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respiratory syndrome during CoViD-19 infection, at the dosage of
400 mg intravenously, in addition to routine therapy. In a few days,
90% of patients recovered and lung opacities disappeared [13], sug-
gesting that anti-IL-6 might be a powerful potential rescue therapy in
respiratory distress syndrome of CoViD-19.
A potential role for anti-IL1 biologics could be hypothesized from
data showing an activation of the NLRP3 inflammasome by SARS-CoV,
with secretion of IL-1β. Studies have demonstrated that inflammasome
activation also occurs in SARS-CoV2 infection, especially within lym-
phoid cells and patients have increased serum IL-1β [14]. Another
potential treatment under evaluation for SARS-CoV2 related acute re-
spiratory disease is baricitinib, an oral drug used to treat rheumatoid
arthritis patients that functions as a blocker of Janus Kinases (JAK) 1
and 2, enzymes associated with intracellular signaling, including Type I
and type II IFN signaling. One rationale for its use is based on the fact
that viruses such as SARS-CoV2 utilize a protein expressed on its spike
to bind to the ACE2 receptor and enter cells through a mechanism of
receptor-mediated endocytosis. One of the known regulators of receptor
mediated endocytosis is a kinase termed the AP2-associated protein
kinase 1 (AAK1). Baricitinib has high affinity for AAK1. Inhibition of
AAK1 is reasoned to not only inhibit receptor mediated endocytosis
(blocking intracellular entry of the virus) but it may also function in the
intracellular assembly of virus particles [15]. The plasma concentration
of baricitinib at its current therapeutic dosage (2 or 4 mg orally once
daily) is sufficient to inhibit AAK1, thus it may be able to reduce both
the viral entry and the inflammation characteristic of CoViD-19 pa-
tients.
Another important aspect in CoViD-19 is that patients are not able
to initiate a valid and rapid type I IFN response [10], but the me-
chanisms underlying this defective response are not completely clear. In
SARS, macrophages and dendritic cells are only abortively infected and
natural killer cells are not activated by the virus, thus suggesting a
defective innate immune response with an altered virus clearance [6].
In a mouse model using the related coronavirus, delayed type-I IFN
responses (with IFN levels peaking later in the immune response and
remaining elevated) were associated with mortality from severe lung
disease, due to recruitment of highly inflammatory macrophages into
the lung [16,17]. Studies of human SARS-CoV infections also strongly
suggest that dysregulated and persistently elevated type-I IFN responses
are associated with severe human lung disease [18]. In the mouse
model, absence of Type-I IFN signaling (achieved by knockout of the
IFN-receptor) abolished lung mediated lethality. These data also sug-
gest a second possible explanation for a therapeutic effect of JAK in-
hibitors such as baricitinib, since they block the downstream signaling
of alpha and beta IFN receptors. The situation is complicated by the
finding that very early administration of IFN-β in the mouse model also
decreased lung disease, suggesting that timing and duration of type-I
IFN responses is critical to whether the outcome is helpful or deleter-
ious [16]. What does this imply for patients on JAK inhibition therapy?
They may have a decreased IFN response to the virus, which would
cause excess virus replication, but they also might have less risk of
severe lung disease due to downregulation of the IFN signaling
pathway. This illustrates the difficult balance between an adequate
immune response to prevent viral replication and an over-exuberant
immune response that causes severe lung pathology [17]. The role of
type I IFN in SARS-CoV2 and the role of blocking IFN-I pathways
therefore requires more detailed studies.
3. The role of the checkpoints inhibitors
The evasion of the immune system checkpoints are often used by
both malignant cancer cells and pathogens to escape immune surveil-
lance. One of the most interesting checkpoint inhibitors is the CD200-
CD200R1 system (Fig. 1). This checkpoint negatively regulates the
immune response with the aim to prevent an excessive inflammatory
response to different triggers [19]. Thus, it has been shown to down-
modulate TLR7 (single strand RNA virus sensor) in plasmacytoid den-
dritic cells of a mouse model of coronavirus infection [20] and to down-
modulate macrophage activation [21]. Interestingly, the inhibition of
CD200-CD200R1 has positive effects on coronavirus infection
[19,20,22], restoring IFN production and increasing virus clearance.
Checkpoint inhibitors are currently and effectively used as therapeutic
agents for a variety of cancers, but have only minimally been studied in
human infectious diseases, although their function was clearly defined
using the murine model of LCMV infection. A CD200-Fc fusion protein
has been successfully used in experimental settings [21] and trials on
inhibitory antibody targeting of CD200 has been tested for the treat-
ment of human cancer [19], thus suggesting the intriguing possibility to
use currently available checkpoint inhibitors for the treatment of
CoViD-19. A trial with another checkpoint inhibitor, anti-PD1, is also
ongoing in CoViD-19 patients.
4. Management of rheumatic patients during the CoViD-19
pandemic
The scientific research on SARS-CoV2 and its possible therapies are
based on the knowledge of previous coronaviruses and on data recently
made available by the Chinese scientific society. Likewise, social and
health policy, information and containment measures are based on
what has been learned from previous epidemics, in order to optimize
the current measures. From the epidemiology of SARS-CoV and SARS-
CoV2 in China we have learned how fundamental are measures such as
early recognition of the problem, strict infection control and identifi-
cation of infected patients, isolation measures, inclusion and formation
of new medical and sanitary staff in the health system, designation of
new hospital wards with appropriate equipment and information
through the mass and social media [14]. As part of these measures,
recently, the Italian Society of Rheumatology has proposed a set of
practical recommendations to improve the management of CoViD-19
patients and to decrease the risk of acquiring this infection in particular
in rheumatic patients undergoing immunosuppressive therapies
(Table 1). In general, the interruption of therapies used in rheumatic
patients is not advised, as it may be responsible for the onset of clinical
flares of the rheumatic disease with subsequent use of other im-
munosuppressants such as oral glucocorticoids that may be equally
unsafe for patients in case of acquired CoViD-19. Although the data are
at present unavailable, it appears important to maintain chronic
therapies and to have a strict control of each patient in order to evaluate
specific clinical needs. In fact, the infection risk in rheumatic diseases
such as rheumatoid arthritis is also related to disease activity and a flare
due to therapy discontinuation would confer a higher risk of infection
[23].
For the same reason, rheumatic patients on long term oral gluco-
corticoid treatment should not only never stop these abruptly but in
addition it should be kept in mind that ending of such therapy may also
lead to adrenal crisis. Prevention measures suggested by the Italian
Table 1
Recommendations proposed for rheumatic diseases during CoViD-19 pandemic.
1- Do not discontinue immunosuppressive treatment
2- Follow the recommendations for infection prevention suggested by the Italian
Ministry of Health, in particular avoid contact with crowded places. Smart
working is encouraged.
3- Chloroquine and hydroxychloroquine seem to have some efficacy on SARS-CoV2
infection.
4- Chronic immunomodulatory therapies, including biologic drugs, must be
guaranteed for rheumatic patients. This includes tocilizumab and baricitinib
availability for patients chronically taking these compounds, as they may start to
be used to treat CoViD-19 severe pneumonia cases.
5- Outpatients clinics, albeit with limited activity, should be guaranteed for biologic
therapies, as the National Health System has authorized people to move for very
specific reasons such as health issues. For all patients, consulting should be made
available using media that exclude a person-to-person relationship.
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Ministry of Health must be applied to everyone, in particular by
rheumatic patients undergoing immunosuppressive therapies. Patients
are therefore strongly encouraged to avoid social contact and maintain
isolation. Chronic therapies will be guaranteed for rheumatic patients
also in these weeks of CoViD-19 outbreak in which the routine out-
patient clinics are closed, as the National Health System has authorized
people to move for very specific reasons such as health issues and the
need for biologic therapies which are available only in some hospitals.
As tocilizumab and baricitinib may start to be used to treat CoViD-19
severe pneumonia cases, their availability must be guaranteed for the
treatment of rheumatic patients who are using these compounds. If a
rheumatic patient develops symptoms of any infection, it is important
to follow the guidelines suggested by the rheumatology community and
immunosuppressive therapy should be paused for the duration of the
infection. The one exception is hydroxychloroquine, which may have
therapeutic potential for CoViD-19 infection and should therefore not
be stopped in patients who have been taking it for a rheumatic disease.
As mentioned above, it is possible that IL-6 blockade and the use of JAK
inhibitors could have beneficial effects on severe lung disease, but we
don't yet know enough to recommend continuing these agents, since
they could adversely affect viral clearance. Much more study of the
kinetics of SARS-CoV2 in the lung, and the relation of the immune re-
sponse to the onset of CRS, is therefore needed to clarify re-
commendations for patients on these agents.
The epidemiological scenario is rapidly changing daily and we still
have no knowledge about the infection rate and course of CoViD-19 in
rheumatologic conditions. Therefore, a national or international reg-
istry is strongly encouraged to understand the impact of the infection
on specific rheumatic diseases or treatments and the risk factors for
poor outcomes. The Italian Society of Rheumatology has established
such a registry in March 2020 and data are being collected. Although
our observations have no epidemiological grounds, we are quite sur-
prised by the limited number of rheumatic patients contacting us be-
cause of a CoViD-19 infection. Furthermore, an international registry
supported by America College of Rheumatology, European League
Against Rheumatism and other rheumatologic societies worldwide is
being launched.
In the meantime, it is important that patients are reassured and
consultations made available using media that exclude a person-to-
person relationship to minimize the risk of infection.
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